Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - Ascentage Pharma

Next Previous
X
Search
Drug Profile

Research programme: anti-cancer therapeutics - Ascentage Pharma

Alternative Names: APG-1022

Latest Information Update: 21 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Apoptosis stimulants; Focal adhesion protein tyrosine kinase inhibitors; Proto-oncogene protein c-akt inhibitors; Proto-oncogene protein c-mdm2 inhibitors; Proto-oncogene protein c-met inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Sep 2023 Preclinical development in Cancer is ongoing in China (Ascentage Pharma website; September 2023)
  • 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in China
  • 16 Apr 2019 Ascentage Pharma plans a phase I trial of APG 2449 for Solid tumours (Late-stage disease, Second-line therapy or greater) in China in May 2019 (PO) (NCT03917043)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top